Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models
Cheng Tang, … , Olga A. Korczeniewska, Rajesh Khanna
Cheng Tang, … , Olga A. Korczeniewska, Rajesh Khanna
Published December 10, 2024
Citation Information: J Clin Invest. 2025;135(4):e177429. https://doi.org/10.1172/JCI177429.
View: Text | PDF
Research Article Neuroscience

C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models

  • Text
  • PDF
Abstract

Antagonists — such as Ziconotide and Gabapentin — of the CaV2.2 (N-type) calcium channels are used clinically as analgesics for chronic pain. However, their use is limited by narrow therapeutic windows, difficult dosing routes (Ziconotide), misuse, and overdoses (Gabapentin), as well as a litany of adverse effects. Expansion of novel pain therapeutics may emerge from mechanism-based interrogation of CaV2.2. Here, we report the identification of C2230, an aryloxy-hydroxypropylamine, as a CaV2.2 blocker. C2230 trapped and stabilized inactivated CaV2.2 in a slow-recovering state and accelerated the open-state inactivation of the channel, conferring an advantageous use-dependent inhibition profile. C2230 inhibited CaV2.2 during high-frequency stimulation, while sparing other voltage-gated ion channels. C2230 inhibited CaV2.2 in dorsal root and trigeminal ganglia neurons from rats, marmosets, and humans in a G-protein-coupled-receptor–independent manner. Further, C2230 reduced evoked excitatory postsynaptic currents and excitatory neurotransmitter release in the spinal cord, leading to relief of neuropathic, orofacial, and osteoarthritic pain-like behaviors via 3 different routes of administration. C2230 also decreased fiber photometry-based calcium responses in the parabrachial nucleus, mitigated aversive behavioral responses to mechanical stimuli after neuropathic injury, and preserved protective pain responses, all without affecting motor or cardiovascular function. Finally, site-directed mutation analysis demonstrated that C2230 binds differently than other known CaV2.2 blockers, making it a promising lead compound for analgesic development.

Authors

Cheng Tang, Kimberly Gomez, Yan Chen, Heather N. Allen, Sara Hestehave, Erick J. Rodríguez-Palma, Santiago Loya-Lopez, Aida Calderon-Rivera, Paz Duran, Tyler S. Nelson, Siva Rama Raju Kanumuri, Bijal Shah, Nihar R. Panigrahi, Samantha Perez-Miller, Morgan K. Schackmuth, Shivani Ruparel, Amol Patwardhan, Theodore J. Price, Paramjit S. Arora, Ravindra K. Sharma, Abhisheak Sharma, Jie Yu, Olga A. Korczeniewska, Rajesh Khanna

×

Figure 3

C2230 inhibits CaV2.2 (N-type) calcium currents and total calcium currents in rat and human dorsal root ganglia sensory neurons, respectively.

Options: View larger image (or click on image) Download as PowerPoint
C2230 inhibits CaV2.2 (N-type) calcium currents and total calcium curren...
(A) Representative traces of N-type calcium currents from rat dorsal root ganglion (DRGs) neurons incubated with 0.1% DMSO (control; blue circles), 5 μM C2230 (orange squares), 10 μM C2230 (purple diamonds) and 50 μM C2230 (pink triangles). (B) Summary of N-type ICa2+ current density-voltage relationship. (C) Bar graphs of peak N-type ICa2+ density from rat DRGs pretreated as indicated. P values as indicated, Kruskal-Wallis test followed by Dunn’s post hoc test, n = 6–28 cells per condition from 3 independent experiments. (D) Paired-pulse voltage protocol for evaluating the possible GPCR-mediated inhibition on CaV currents, in which the +100 mV/100 ms strong depolarization was used to drive Gβγ dissociation from the CaV channels. (E) Typical DRG total CaV current traces elicited by the paired-pulse voltage protocol in (D), in the absence (DMSO) or presence of 20 μM C2230. (F) Summary I2/I1 ratio in (E) (P values as indicated, Mann-Whitney test n = 6–7 from 2 independent experiments). (G) Representative traces of total calcium currents from human DRGs incubated with 0.1% DMSO (control; blue circles) or 20 μM C2230 (orange squares). (H) Summary of total ICa2+ current density-voltage relationship. (I) Bar graphs of peak total ICa2+ density from human DRGs pretreated as indicated. P values as indicated, Mann-Whitney test, n = 6–7 cells per condition from 1 independent experiment. Error bars indicate mean ± SEM. See Supplemental Table 3 for full statistical analysis.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts